Medtronic sells PDN (prostatic disc nucleus) device in Europe and India:
This article was originally published in Clinica
Executive Summary
Medtronic Sofamor Danek is to sell Raymedica's prostatic disc nucleus (PDN) in Europe and India and has made an undisclosed equity investment in the development-stage company. The PDN, which is for the treatment of low back pain for patients not responding to conservative care, is made of a hydrogel material that is designed to replace the function of a failed spinal disc nucleus. Medtronic has negotiation rights for further territories and will also collaborate with Raymedica on new instrumentation development. No further details are yet available.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.